Related Experiment Video
Updated: Jul 12, 2025

Transverse Aortic Constriction in Mice
Published on: April 21, 2010
CD9 exacerbates pathological cardiac hypertrophy through regulating GP130/STAT3 signaling pathway
Yue Li1,2, Siyuan Fan3, Lingyao Kong1
1Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.
Insights
CD9 protein exacerbates pathological cardiac hypertrophy by interacting with GP130 and activating the STAT3 pathway. Reducing CD9 expression improves cardiac function and reduces hypertrophy markers.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- CD9, a tetraspanin protein, is implicated in inflammation and cancer.
- Its role in pathological cardiac hypertrophy remains largely unexplored.
Purpose of the Study:
- To investigate the role of CD9 in pathological cardiac hypertrophy.
- To elucidate the underlying molecular mechanisms involving CD9 in cardiac hypertrophy.
Main Methods:
- Utilized a transaortic constriction (TAC) mouse model to induce cardiac hypertrophy.
- Employed CD9 knockdown and co-immunoprecipitation assays.
- Assessed cardiac function, heart weight, cardiomyocyte size, fibrosis, GP130 levels, and STAT3 phosphorylation.
Main Results:
- CD9 expression was upregulated in TAC-induced myocardial tissue.
- CD9 knockdown ameliorated cardiac dysfunction, reduced heart weight, cardiomyocyte size, and fibrosis.
- CD9 directly binds to GP130, reducing GP130 protein levels and STAT3 phosphorylation.
- GP130 knockdown counteracted the detrimental effects of CD9 on cardiac hypertrophy.
Conclusions:
- CD9 exacerbates pathological cardiac hypertrophy by modulating the GP130/STAT3 signaling pathway.
- CD9 represents a potential therapeutic target for treating pathological cardiac hypertrophy.
Abstract:
CD9 is a member of the tetraspanin protein family, which has been widely studied in inflammation and cancer, but not in pathological cardiac hypertrophy. In this study, we found that the expression of CD9 was increased in transaortic constriction (TAC) myocardial tissue. Knockdown of CD9 alleviated damage to cardiac function in the TAC model and reduced heart weight, cardiomyocyte size, and degree of fibrosis, and vice versa. Mechanistically, co-immunoprecipitation results showed that CD9 and GP130 can bind to each other in cardiomyocytes, and knockdown of CD9 can reduce the protein level of GP130 and the phosphorylation of STAT3 in vivo and in vitro, and vice versa. GP130 knockdown reversed the aggravating effects of CD9 on pathological cardiac hypertrophy. Therefore, we conclude that CD9 exacerbates pathological cardiac hypertrophy by regulating the GP130/STAT3 signaling pathway and may serve as a therapeutic target for pathological cardiac hypertrophy.
More Related Videos
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
10:18Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
Published on: June 29, 2014
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology
GPCRs Regulate Adenylyl Cylase Activity
Cardiomyopathy II: Dilated Cardiomyopathy
Amplifying Signals via Enzymatic Cascade
Cardiomyopathy V: Interprofessional Care